AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions, and listings, of claims in this application.

Listing of Claims

1-6. (Canceled)

7. (Currently Amended) A composition comprising a protein in crystalline form wherein the protein consists of SEQ ID NO:5, wherein said protein forms a complex with an inhibitor ligand and wherein the protein crystal has a crystal lattice in a $P2_12_12_1$ space group and unit cell dimensions, +/- 5%, of a=92.1Å, b= 97.6Å, c=138.9Å, and $\alpha=\beta=\gamma=90°$.

8. (Currently Amended) The composition according to claim 7 wherein the protein ~~is present in the protein crystal as a trimer~~ crystal unit cell comprises three protein molecules.

9. (Canceled)

10. (Previously Presented) The composition according to claim 7 wherein the protein crystal diffracts X-rays for a determination of structure coordinates to a resolution of a value equal to or less than 3.0 Angstroms.

11-24. (Canceled)

25. (Currently Amended) A method comprising:

forming a crystallization volume comprising a precipitant solution and a protein that consists of SEQ ID NO:5, wherein said protein forms a complex with an inhibitor ligand and wherein the protein crystal has a crystal lattice in a $P2_12_12_1$ space group and unit cell dimensions, +/- 5%, of a=92.1Å, b= 97.6Å, c=138.9Å, and $\alpha=\beta=\gamma=90°$; and

storing the crystallization volume under conditions suitable for crystal formation of the protein.

26. (Currently Amended) The method according to claim 25 wherein the protein ~~crystallizes as a trimer~~ crystal unit cell comprises three protein molecules.

27. (Canceled)

28. (Previously Presented) The method according to claim 25 wherein a protein crystal is produced that diffracts X-rays for a determination of structure coordinates to a resolution of a value equal to or less than 3.0 Angstroms.

29-30. (Canceled)

31. (Previously Presented) The method according to claim 25 wherein a protein crystal is produced, the method further comprising:

diffracting the protein crystal to produce a diffraction pattern; and

solving the structure of the protein from the diffraction pattern.

32-43. (Canceled)

44. (Currently Amended) A non-crystalline protein consisting of SEQ ID NO:5.

45. (Previously Presented) The method according to claim 31, the method further comprising:

performing rational drug design using the solved structure; and

identifying an entity that associates with the protein crystal.

46. (Currently Amended) The method according to claim 45 wherein the protein ~~is present in the protein crystal as a trimer~~ crystal unit cell comprises three protein molecules.

47-48. (Canceled)

49. (Previously Presented) The method according to claim 45, the method further comprising selecting one or more entities based on the rational drug design and contacting the selected entities with the protein.

50. (Previously Presented) The method according to claim 45, the method further comprising measuring an activity of the protein when contacted with the one or more entities.

51. (Previously Presented) The method according to claim 45, the method further comprising comparing activity of the protein in a presence of and in the absence of the one or more entities; and selecting entities where activity of the protein changes depending whether a particular entity is present.

52. (Previously Presented) The method according to claim 45, the method further comprising contacting cells expressing the protein with the one or more entities and detecting a change in a phenotype of the cells when a particular entity is present.

53. (New) An isolated non-crystalline protein consisting of SEQ ID NO:5.